Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from AbbVie Inc, Constellation Pharmaceuticals, Inc., and Incyte Corporation.

Advances in™: What Does the Future Hold for Treatment and Management of MPNs?

Release Date: April 30, 2021
Expiration Date: April 30, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of MPNs, with a forward-looking perspective of how novel agents might impact clinical practice. The essentials of risk stratification and molecular testing, clinical trial data, current and emerging treatment strategies, and the management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with an expert thought leader, integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc, Constellation Pharmaceuticals, Inc., and Incyte Corporation.


Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward hematologists and medical oncologists interested in the treatment of hematologic malignancies. Other allied health care professionals, including nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the role of clinical and cytogenic characteristics in risk stratification and treatment planning for the management of myeloproliferative neoplasms (MPNs)
  • Assess the rationale for, as well as efficacy and safety data from, ongoing clinical trials evaluating emerging therapies for the treatment of myelofibrosis (MF) and polycythemia vera (PV)
  • Determine eligible patients with MF or PV based on disease characteristics who may benefit from participation in a clinical trial

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.


Ruben A. Mesa, MD, FACP
Ruben A. Mesa, MD, FACP
Executive Director
Mays Cancer Center
University of Texas Health San Antonio MD Anderson Cancer Center
San Antonio, TX

Disclosures: Grant Research Support: Bristol Myers Squibb, CTI BioPharma, Incyte Corporation, Sierra Oncology; Consultant: AbbVie, Blueprint, Bristol Myers Squibb, Incyte Corporation, Novartis, Protagonist Therapeutics, Telios pharma.

Naveen Pemmaraju, MD
Naveen Pemmaraju, MD
Associate Professor
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Program
Hematology Consultant, Cancer Network
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures: Grant/Research Support: Affymetrix, SagerStrong Foundation. Consultant: AbbVie, Blueprint Medicines, Bristol Myers Squibb, Celgene, DAVA Oncology, ImmunoGen, Incyte, LFB Biotechnologies, MustangBio, Novartis, Pacylex Pharmaceuticals, Roche Diagnostics, Sprinter Science + Business Media, Stemline Therapeutics.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By